Circulating anti-p53 antibodies in liver cancer patients
Author Information
Author(s): Saffroy R, Lelong J-C, Azoulay D, Salvucci M, Reynes M, Bismuth H, Debuire B, Lemoine A
Primary Institution: Service de Biochimie, Hôpital Paul Brousse, Villejuif Cedex, France
Hypothesis
The presence of anti-p53 serum antibodies may indicate a better prognosis in hepatocellular carcinoma patients.
Conclusion
Anti-p53 serum antibodies may serve as a marker of better prognosis in some hepatocellular carcinoma patients.
Supporting Evidence
- Nine (7%) HCC patients had anti-p53 serum antibodies before treatment.
- All negative patients remained negative during a mean follow-up of 30 months.
- Eight of the nine positive patients remained positive 12–30 months after surgery.
- A greater incidence of vascular invasion was observed in the tumors of patients with anti-p53 antibodies.
- Accumulation of p53 protein was higher in tumors of patients with anti-p53 antibodies.
- Patients with anti-p53 antibodies had a better survival rate without recurrence.
Takeaway
Some liver cancer patients have antibodies that might mean they will do better after treatment.
Methodology
Anti-p53 serum antibodies were assessed using ELISA on 130 patients, and immunohistochemistry was performed on tumors from 52 patients.
Limitations
The study did not find a correlation between anti-p53 antibodies and p53 gene mutations or serum alpha-fetoprotein levels.
Participant Demographics
European patients with hepatocellular carcinoma.
Statistical Information
P-Value
P < 0.03 and P < 0.01 for vascular invasion and p53 protein accumulation respectively; P = 0.05 for survival rate without recurrence.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website